Gilead announces two public-private partnerships

Gilead Sciences is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide. The second aims to develop investigational pediatric formulations of TAF and sofosbuvir designed to eliminate bitterness. For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead is partnering with the Clinton Health Access Initiative and the Penta ID network, a scientific organization dedicated to child health research, to accelerate the development, regulatory approval and commercialization of a dispersible, fixed-dose combination treatment for the treatment of children with HIV who weigh at least 3 kg and live in low- and middle-income countries. This regimen will include Gilead’s products F/TAF. Under the terms of the agreement, Gilead will provide a technology transfer of currently available data for a dispersible formulation of F/TAF and supporting pharmacokinetic data. Penta, within the UNIVERSAL project which is funded by the European & Developing Countries Clinical Trials Partnership, will develop PK modelling and clinical studies for the investigational combination formulation, and CHAI, with support from global health agency Unitaid, will be responsible for the global access strategy in collaboration with two generic manufacturers. Gilead is also partnering with Monell Chemical Senses Center, Eurofins’ Translational Cell Models group (formerly known as DiscoveryBiomed, and CHAI to identify bitter blockers for pediatric formulations of the medications TAF and SOF. Identifying bitter blockers for these medications may help to improve adherence to medication among children. Pediatricians, caregivers, industry and global health donors all acknowledge that bitter taste in medication for children, who are particularly sensitive to bitterness, can contribute to low adherence rates, which in turn increase the potential for morbidities and mortality in young patients. Once candidate bitter blockers are confirmed, the partners will then work together to see these agents move on to product development and eventual introduction, if approved.